Research progress in drug therapy for relapsed/refractory multiple myeloma
Liu Tingyu
Xiong Jie
Zhang Yan
Abstract：The management of relapsed/refractory multiple myeloma(RRMM)remains a formidable challenge due to disease heterogeneity and drug resistance.Recent years have witnessed a paradigm shift from conventional chemotherapy to tar-geted and immunotherapeutic strategies.This article comprehensively reviews the progress in drug therapy for RRMM.While traditional targeted agents,including proteasome inhibitors and immunomodulatory drugs,continue to evolve and break efficacy barriers through structural optimization and combination regimens,novel immunotherapies-such as monoclonal antibodies,anti-body-drug conjugates,bispecific antibodies,and chimeric antigen receptor T-cell(CAR-T)therapies-have demonstrated unprec-edented efficacy in achieving deep and durable responses,even in heavily pretreated patients.The future of RRMM clinical man-agement lies in biomarker-guided precision medicine,mechanism-driven combination therapies,and the forward deployment of the most effective treatments,ultimately aiming to transform RRMM into a chronic and controllable condition.
Keywords：Relapsed/refractory multiple myelomaTargeted drugsImmunotherapyCombined therapy
Publication Date：2026-01-18
Online Publishing Date：2026-02-04(First online date of this platform, not the publication date of the document)
Pages：5( 111-115 )